Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Real-World Treatment Patterns and Outcomes for Patients With Metastatic Triple-Negative Breast Cancer in the United States: An Observational Study.
Journal: JCO oncology practice
Published: January 07, 2026
Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.
Journal: Breast cancer research : BCR
Published: August 25, 2025
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
Journal: Breast cancer research : BCR
Published: June 09, 2025
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.
Journal: ESMO open
Published: January 17, 2025
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.
Journal: Clinical breast cancer
Published: August 26, 2024
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Journal: Breast cancer research and treatment
Published: July 13, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 08, 2024
Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 21, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Journal: Breast cancer research and treatment
Published: March 11, 2024
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.
Journal: Breast cancer research and treatment
Published: January 08, 2024
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
Journal: The Journal of clinical investigation
Published: October 04, 2023
Last Updated: 09/26/2026